{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:57:27Z","timestamp":1760237847576,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ecl.2021.03.003","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T05:45:20Z","timestamp":1619588720000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays"],"prefix":"10.1016","volume":"50","author":[{"given":"Robert A.","family":"Adler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2021.03.003_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00198-017-4345-0","article-title":"Hip fracture in the United States, 2002 to 2015","volume":"29","author":"Lewiecki","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2021.03.003_bib2","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jbmr.2202","article-title":"Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011","volume":"29","author":"Solomon","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.003_bib3","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"396","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2021.03.003_bib4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effects of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension of the HORIZON[Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.003_bib5","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.2565","article-title":"Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis","volume":"30","author":"Jha","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.003_bib6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","article-title":"Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research","volume":"31","author":"Adler","year":"2016","journal-title":"J\u00a0Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2021.03.003_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis -2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2021.03.003_bib8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacologic management of Reid osteoporosis in postmenopausal women: an endocrine society clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2021.03.003_bib9","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five years of anti-resorptive activity after a single dose of zoledronate: results from a randomized double-blind placebo-controlled trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2021.03.003_bib10","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2021.03.003_bib11","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4158\/EP10059.OR","article-title":"Zoledronic acid treatment of osteoporosis: effects in men","volume":"19","author":"Johnson","year":"2010","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2021.03.003_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12020-015-0748-x","article-title":"Duration of anti-resorptive therapy for osteoporosis","volume":"51","author":"Adler","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.ecl.2021.03.003_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice: postmenopausal osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2021.03.003_bib14","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2021.03.003_bib15","doi-asserted-by":"crossref","first-page":"e0122646","DOI":"10.1371\/journal.pone.0122646","article-title":"Bisphosphonates and risk of cardiovascular events: a meta-analysis","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ecl.2021.03.003_bib16","doi-asserted-by":"crossref","DOI":"10.1177\/2042098619838138","article-title":"Bisphosphonates and cardiovascular risk in elderly patients with previous cardiovascular disease: a population-based nested case-control study in Italy","volume":"10","author":"Kirchmayer","year":"2019","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.ecl.2021.03.003_bib17","doi-asserted-by":"crossref","first-page":"102454","DOI":"10.1016\/j.jaut.2020.102454","article-title":"Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors: results from the WHO\u2019s pharmacovigilance database","volume":"111","author":"Anquetil","year":"2020","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.ecl.2021.03.003_bib18","doi-asserted-by":"crossref","first-page":"E431","DOI":"10.1503\/cmaj.111752","article-title":"Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study","volume":"184","author":"Etminan","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.ecl.2021.03.003_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00198-014-2872-5","article-title":"Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial","volume":"26","author":"Patel","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.ecl.2021.03.003_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00223-015-0015-4","article-title":"The effects of re-challenge in patients with a history of acute anterior uveitis following intravenous zoledronate","volume":"97","author":"Patel","year":"2015","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.ecl.2021.03.003_bib21","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a Task Force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.003_bib22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.003_bib23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1177\/1060028016649368","article-title":"Identification of risk factors for bisphosphonate-associated atypical femoral fractures and osteonecrosis of the jaw in a pharmacovigilance database","volume":"50","author":"Bejhed","year":"2016","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ecl.2021.03.003_bib24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis","volume":"142","author":"Hellstein","year":"2011","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.ecl.2021.03.003_bib25","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.003_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a Task Force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.ecl.2021.03.003_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s00774-016-0790-7","article-title":"Atypical femoral fractures in Italy: a retrospective analysis in a large urban emergency department during a 7-year period (2007-2013)","volume":"35","author":"Pedrazzoni","year":"2017","journal-title":"J\u00a0Bone Miner Metab"},{"key":"10.1016\/j.ecl.2021.03.003_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/er.2018-00001","article-title":"Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management","volume":"40","author":"Black","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ecl.2021.03.003_bib29","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2021.03.003_bib30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3109\/17453674.2014.916488","article-title":"Histology of 8 atypical femoral fractures: remodeling but no healing","volume":"85","author":"Schilcher","year":"2014","journal-title":"Acta Orthopaedica"},{"key":"10.1016\/j.ecl.2021.03.003_bib31","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1016\/j.injury.2017.09.023","article-title":"Location of atypical femoral fracture can be determined by tensile stress distribution influenced by femoral bowing and neck-shaft angle: a CT-based nonlinear finite element analysis model for the assessment of femoral shaft loading stress","volume":"48","author":"Oh","year":"2017","journal-title":"Injury"},{"key":"10.1016\/j.ecl.2021.03.003_bib32","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.bone.2016.01.002","article-title":"The association of race\/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy","volume":"85","author":"Lo","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.ecl.2021.03.003_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/M19-0533","article-title":"Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review","volume":"171","author":"Fink","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ecl.2021.03.003_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/cen.13012","article-title":"Changes in bone mineral density and bone turnover in patients on \u2018drug holiday\u2019 following bisphosphonate therapy: real-life clinic setting","volume":"84","author":"Roberts","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ecl.2021.03.003_bib35","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1007\/s00198-017-4215-9","article-title":"Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk","volume":"28","author":"Mignon","year":"2017","journal-title":"Osteoporos Int"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921000153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852921000153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:45:23Z","timestamp":1760175923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852921000153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0889852921000153"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2021.03.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"type":"print","value":"0889-8529"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on Rare Adverse Events from Osteoporosis Therapy and Bisphosphonate Drug Holidays","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2021.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}